Jennifer Fink | Authors


Treatment Options for HER2+ Breast Cancer Open to Multiple Lines of Therapy and Subgroups

October 20, 2020

Until recently, few options existed for patients with HER2-positive breast cancer who progressed on earlier lines of therapy. Recent approvals of 3 drug combinations offer new tools that may prolong life and control brain metastases across lines of therapy.

More Actionable Targets Improve Therapy in NSCLC

July 16, 2019

Advances in targeted therapies show encouraging activity as treatment for tough-to-target driver alterations in non–small cell lung cancer emerge, according to data presented at the 2019 ASCO Annual Meeting. The discovery of additional oncogenic drivers and promising targeted therapies means that certain patients will receive treatments that produce favorable outcomes based on their disease characteristics.

Immunotherapy Combinations Are Changing the Frontline Treatment of Patients With NSCLC

August 16, 2018

Checkpoint inhibitors are revolutionizing the treatment of patients with both squamous and nonsquamous non-small cell lung cancer, and are quickly assuming a predominant role, especially in the frontline setting, due to recent exciting results from large trials.

Identifying and Managing Immune-Related Adverse Events

February 20, 2018

As checkpoint inhibition is increasingly being utilized beyond the scope of clinical trials, it’s essential that community-based oncologists and physicians learn how to quickly diagnose and treat immune-related adverse events.